MedTrace Logo

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea

NCT04446039 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 370212

Last updated 2024-12-09

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to investigate medication utilization pattern and risk of adverse outcomes among commonly used antidepressants by using nationwide claims database, in order to assess overall clinical benefit of antidepressant therapy in real-world practice.

Conditions

Interventions

DRUG

Escitalopram

Treatment for depression

DRUG

Paroxetine

Treatment for depression

DRUG

Fluoxetine

Treatment for depression

DRUG

Mirtazapine

Treatment for depression

DRUG

Duloxetine

Treatment for depression

DRUG

Sertraline

Treatment for depression

DRUG

Venlafaxine

Treatment for depression

DRUG

Tianeptine

Treatment for depression

DRUG

Vortioxetine

Treatment for depression

DRUG

Desvenlafaxine

Treatment for depression

DRUG

Bupropion

Treatment for depression

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-04
Primary Completion
2022-11-03
Completion
2022-11-03
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04446039 on ClinicalTrials.gov